Multiple healthcare policy changes are converging to create unprecedented uncertainty for key opinion leaders and their patients. HR 1 implementation beginning January 2027, and enhanced premium subsidies for ACA marketplace plans expire at the end of 2025. The Inflation Reduction Act’s drug price negotiation program continues to reshape formulary decisions and prior authorization requirements. Most Favored Nation policies under consideration could further impact access to medications and medical devices.
For Medical Science Liaisons, these policy shifts directly affect the patient populations that KOLs treat, prescribing patterns MSLs observe, and the conversations that emerge during scientific exchanges. Understanding these implications helps MSLs maintain productive relationships while navigating sensitive topics professionally.
How Policy Changes Affect KOL Priorities
Key opinion leaders increasingly manage patient populations with unstable insurance coverage. This reality affects their clinical decision-making, research interests, and the types of scientific discussions they value with MSLs.
Research priorities shift as KOLs observe more patients struggling with access issues. Academic physicians become more interested in studies examining treatment interruption effects, medication adherence during coverage transitions, or simplified treatment regimens for patients with unstable insurance.
Maintaining Scientific Integrity During Access Discussions
MSLs must balance providing valuable scientific information with addressing legitimate access concerns without crossing promotional boundaries. This requires a clear understanding of appropriate scientific dialogue versus promotional activities.
Scientific discussions about treatment adherence, disease progression, and outcome optimization remain entirely appropriate even when coverage issues provide the context. MSLs can share published research on medication adherence challenges, discuss clinical studies examining treatment interruption effects, and provide data on simplified treatment regimens without making promotional claims.
Real World Evidence (RWE) becomes valuable during these conversations. KOLs treating patients with unstable coverage appreciate data showing how treatments perform under less-than-ideal adherence conditions. Studies examining treatment effectiveness in diverse patient populations or resource-constrained settings provide relevant scientific context for clinical decision-making.
However, MSLs must avoid making direct connections between scientific data and specific access programs or suggesting that their company’s products are preferred solutions for coverage challenges. The focus should remain on objective scientific information that helps KOLs make informed clinical decisions rather than steering toward therapeutic choices.
Supporting KOLs Through Evidence and Education
KOLs managing patients with unstable coverage benefit from scientific information that helps them optimize outcomes despite access challenges. MSLs can provide valuable support through evidence-based education that addresses real clinical needs without promotional bias.
Adherence research takes on increased relevance when patients face coverage disruptions. MSLs can share studies examining factors that influence medication adherence, interventions that improve treatment compliance, and outcomes associated with different adherence patterns.
Comparative effectiveness research helps KOLs make informed decisions when formulary restrictions or coverage limitations affect treatment options. Studies comparing clinical outcomes, safety profiles, and real-world effectiveness across different therapeutic approaches provide objective information for clinical decision-making.
Health economics and outcomes research gains importance as KOLs increasingly participate in value-based care arrangements or institutional cost management initiatives. MSLs with expertise in pharmacoeconomic studies and budget impact analyses provide a valuable scientific perspective on treatment value propositions.
Adapting Engagement Strategies
Traditional KOL engagement models may require modification as healthcare delivery patterns change in response to policy pressures. MSLs should consider how coverage uncertainties affect KOL availability, priorities, and preferred communication methods.
Virtual engagement becomes more important as KOLs manage increased patient loads and administrative burdens. MSLs should develop proficiency in conducting meaningful scientific discussions through digital platforms while maintaining personal relationships.
Timing considerations change when KOLs face increased clinical demands due to coverage disruptions. MSLs may need to offer more flexible scheduling options and shorter, more focused interactions that respect time constraints while providing valuable scientific information.
Regional variations in policy implementation require MSLs to understand local conditions that affect their KOLs. States implementing work requirements at different times or with varying verification approaches create different challenges for KOLs in different geographic areas.
Professional Development for Policy-Aware MSLs
The evolving healthcare landscape requires MSLs to develop new competencies that complement traditional clinical and scientific skills. Understanding policy implications helps MSLs anticipate KOL needs and provide more relevant scientific support.
Health policy literacy is becoming increasingly important for MSLs working in policy-sensitive therapeutic areas. Understanding how healthcare financing works, what drives coverage decisions, and how policy changes affect patient access helps MSLs have more informed discussions with KOLs facing these challenges.
Health economics knowledge helps MSLs understand the broader context of clinical decision-making when budget pressures intensify. Basic understanding of pharmacoeconomic principles, value-based care concepts, and institutional cost management enables more sophisticated scientific discussions.
Ethical Considerations and Compliance
Policy-driven access challenges create new compliance considerations for MSL activities. A clear understanding of appropriate boundaries helps maintain scientific integrity while providing valuable support to KOLs.
Avoiding promotional implications requires careful attention to language and positioning when discussing access-related topics. MSLs should focus on providing objective scientific information rather than suggesting solutions that favor their company’s products or programs.
Documentation standards become more important when conversations touch on sensitive topics like patient access or coverage challenges. Clear records of scientific discussions help demonstrate appropriate professional conduct and compliance with regulatory requirements.
Building Long-Term Value
Healthcare policy uncertainty creates opportunities for MSLs to demonstrate value through consistent, reliable scientific support that helps KOLs navigate challenging clinical situations. Building trust during difficult periods strengthens relationships for long-term collaboration.
Proactive communication helps KOLs prepare for policy changes that may affect their practices. MSLs who understand policy timelines and implications can provide advance notice of potential changes, allowing KOLs to plan appropriate responses.
Resource sharing becomes more valuable when KOLs face new challenges. MSLs who can provide relevant clinical guidelines, treatment algorithms, or patient education materials help KOLs adapt their practices efficiently.
The key is recognizing that policy changes affect the environment in which scientific discussions occur without changing the fundamental importance of objective, evidence-based information sharing. MSLs who adapt their approaches while maintaining scientific integrity will continue providing valuable support to the healthcare community during uncertain times.
About the author:
Keith Willis
Keith Willis is the President of Core Management Training. His experience includes sales, sales leadership, operations, and sales training in diverse therapeutic areas. He has worked with several large pharmaceutical companies including Ciba Geigy, Johnson and Johnson, Wyeth, Pfizer, Otsuka, and Bristol Myers Squibb. Keith utilizes his rich experience to offer tailored solutions that empower clients from various sectors to achieve excellence in their performance.
Have an opinion on this article? Send a message to the editor.